Dear Mel,
Thank you so much for that contribution. I believe and support the
viewpoint that the more information about new treatments and ongoing
clinical trials brings us that much closer to cures and the very
importance of receiving and believing there is HOPE. thank you so much
for that.
God Bless
marty
surfeit@hotmail.com wrote:
>
> Magainin Outlines Development Status of Angiogenesis Program
>
> PLYMOUTH MEETING, Pa., May 4 /PRNewswire/ -- Magainin Pharmaceuticals
> Inc. today outlined the development status of squalamine, its
> angiogenesis inhibitor for the treatment of patients with solid tumors.
>
> Squalamine is being evaluated in human Phase I clinical testing at two
> sites, the Cancer Therapy and Research Center, San
> Antonio, Texas under the direction of Dr. Gail Eckhardt and the Lombardi
> Cancer Center, Georgetown University under the
> direction of Dr. Michael Hawkins. The objective of the Phase I clinical
> trials is to assess the safety and pharmacokinetics of
> intravenously administered squalamine in cancer patients. This
> information will be used to design subsequent efficacy trials in
> individuals with advanced stage malignancies using squalamine alone and
> in combination with commonly administered
> chemotherapeutic agents.
>
> Magainin has reported extensive preclinical data on squalamine,
> including collaborative work conducted by Dr. Joan Schiller,
> University of Wisconsin Cancer Center; work conducted by Dr. Henry Brem
> at The Johns Hopkins University School of
> Medicine; work conducted by Dr. Daniel Von Hoff at the Institute for
> Drug Development; and work conducted by Dr.
> Beverly Teicher formerly of the Dana Farber Cancer Institute. These
> studies have shown squalamine to be efficacious in the
> inhibition of various cancers in animals, including lung, breast, brain
> and melanoma.
>
> ``The recent publicity regarding the role of angiogenesis in the
> treatment of cancer has intensified interest in our squalamine
> program,'' said Jay Moorin, Chairman, President and Chief Executive
> Officer of Magainin. ``The success of squalamine in
> preclinical testing, both in our hands and in the hands of a number of
> cancer experts, has led us to the commencement of
> human clinical studies. We are pleased with the focus on the field of
> angiogenesis, an approach which has been the principal
> focus of our cancer program.''
>
> Squalamine was discovered in 1992 in the body tissues of the dogfish
> shark by a team led by Michael Zasloff, M.D., Ph.D.,
> Executive Vice President of Magainin. It is the first of a novel class
> of naturally occurring pharmacologically active small
> molecules (the ``aminosterols'') under development at Magainin as human
> therapeutics. Squalamine has been shown in
> preclinical studies to be a new type of inhibitor of angiogenesis.
> Angiogenesis is the process of budding and growth of new
> blood vessels from existing blood vessels under the stimulus of a
> variety of growth factors. Squalamine inhibits the growth of
> tumor-induced new blood vessels in animal systems and also reduces the
> spread of tumor metastases.
>
> Magainin Pharmaceuticals Inc. is a biopharmaceutical company engaged in
> the development of medicines for serious diseases.
> The Company's development efforts are focused on anti-infectives,
> oncology, and pulmonary and allergic disorders.
>
> Mel
>
> ______________________________________________________
> Get Your Private, Free Email at http://www.hotmail.com
>
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
